Is Gardasil Worth the Risk?

by | May 12, 2009


MY GIRL DIED AS ‘GUINEA PIG’ FOR GARDASIL

A green chalkboard with the message 'I LOVE YOU' written in white chalk.

New York Post Article: July 20, 2008

On the advice of her family doctor, Jessie Ericzon, 17, had taken a series of three Gardasil shots to prevent cervical cancer caused by the sexually transmitted virus known as HPV – the Human Papilloma Virus.
The vaccine is marketed by Merck Pharmaceuticals & Co. as the hip thing to do for girls age 9-26 to prevent cervical cancer. Jessie got her first injection in July 2007.
After her second shot in September, she complained to her mom of a pain in the back of her head, fatigue and soreness in some joints.
The day following her 3rd and final shot, she again complained of the nagging pain in the back of her head.
The next day she didn’t show up at school and her mother found her dead on the bathroom floor at home.

Jessica’s mom, Lisa Ericzon, believes the vaccine killed her daughter and that she was “a guinea pig” for Merck & Co. She is urging parents to research the vaccine before letting their daughters get it.

“I want other mothers to know,” said Lisa, the first parent of a girl who died after Gardasil to speak publicly.

“I don’t want them to go through what I went through.”

To learn more about the Jessica’s story, click here to read the article written by Susan Edelman that appeard about her in the New York Post on July 8, 2008.

Deadly Decision: Should you vaccinate yourself or your daughter with Gardasil?

The Federal Vaccine Adverse Event Reporting System (VAERS) had documented 10,000 cases of adverse events that closely followed the administration of the Gardasil vaccine. VAERS reports include serious neurological disorders, dizziness, fainting, muscle and joint pains, and at least 29 deaths after Gardasil . This vaccine is being marketed by Merck & Co., as a vaccine to prevent Cervical Cancer. The truth is this vaccine does not prevent cancer at all. It is licensed only to prevent 2 of the 30 sexually transmitted types of HPV virus that may cause cervical cancer.A green chalkboard with the message 'I LOVE YOU' written in white chalk.
Many experts believe that the adverse reactions to this vaccine are under reported, and not worth the risks since HPV is a preventable disease for which there is a safe and effective non-surgical treatment. Even though severe adverse reactions and deaths linked to the vaccine continue to mount, the FDA continues to claim the benefits outweigh the risks.

The side effects of Gardasil include pain, swelling, itching, bruising, and redness at the injection site, headache, fever, nausea, dizziness, vomiting, and fainting, paralysis and death. GARDASIL is given as 3 injections over 6 months.

Gardasil was tested in four clinical studies that evaluated 20,541 women who were 16 to 26 years of age at enrollment and was followed for a maximum of 4 years. The vaccine was “Fast-tracked” by the FDA and is therefore still in the testing stages with the final report not due until September 30, 2009. However, Gardasil is already being administered to millions of girls, some as young as 9 years old. Some states have already made Gardasil a mandatory vaccination although this recommendation has been opposed by the American College of Pediatrics and the editors of The New England Journal of Medicine.

The Gardasil Vaccine contains only 4 of the 30 types of the HPV virus known to be associated with causing cervical cancer. (Types 6, 11, 16 and 18). The massive advertising campaign for Gardasil by Merck & Co., claims that it is “the only vaccine that may help protect you from the four types of Human Papilloma virus that may cause 70% of cervical cancer.” However, research published in JAMA, Feb 28, 2007, revealed that only 3.4% of young girls and women that get HPV are infected with one of the four HPV types that are included in the Gardasil vaccine. The JAMA researchers concluded that the 26.8% overall prevalence of HPV among women was higher than expected, but that very few cases included the HPV types found in the vaccine.

The fact is, Gardasil has not been proven to be safe or effective. Even more concerning, long-term risks are not yet known. The HPV Vaccine contains 225mcg of Aluminum, a known neurotoxin and 50mcg of Polysorbate 80, which has been shown to cause severe anaphylactic reactions.

As of June 2008, Judicial Watch, a public interest group that investigates questionable government, legal and judicial actions, obtained documents from the U.S. Food and Drug Administration under the Freedom of Information Act that revealed the:

•”Information has been received … concerning a 17 year old female who in June 2007 … was vaccinated with a first dose of Gardasil … During the evening of the same day, the patient was found unconscious (lifeless) by the mother. Resuscitation was performed by the emergency physician but was unsuccessful. The patient subsequently died.”

•”Information has been received … concerning a 12 year old female with a history of aortic and mitral valve insufficiency … who on 01-MAR-2007 was vaccinated IM into the left arm with a first does of Gardasil … On 01-MAR-2007 the patient presented to the ED with ventricular tachycardia and died.”

•”Initial and follow-up information has been received from a physician concerning an ‘otherwise healthy’ 13 year old female who was vaccinated with her first and second doses of Gardasil. Subsequently, the patient experienced … paralysis from the chest down, lesions of the optic nerve…At the time of the report, the patient had not covered.”

For more information about the concerns about the safety of this vaccine and reports of side-effects, click here: www.judicialwatch.org/gardasil

For more information about Gardasil, HPV and Cervical Cancer click here to read Dr. Hansen’s post entitled: Natural Non-Surgical Treatment for HPV.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

4 + 12 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });